ReproCell Stock

ReproCell Gross Profit

The Gross Profit of ReproCell (4978.T) as of Aug 11, 2026 is 1.65 B JPY. In the previous year, Gross Profit was 1.12 B JPY — a change of 47.11% (higher).

Gross Profit

1.65 BJPY

YoY

47.11%

Last updated:

Gross Profit of ReproCell is 2026 1.65 B JPY. Gross Profit of ReproCell was 2025 1.12 B JPY. It decreases by 47.11% higher compared to the previous year.

The ReproCell Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2020
39.56 base
Jan 1, 2021
37.53 base
Jan 1, 2022
35.95 base
Jan 1, 2023
38.64 base
Jan 1, 2024
46.19 base
Jan 1, 2025
55.36 base
Jan 1, 2026 (e)
52.02 base
Jan 1, 2027 (e)
46.72 base
YEARGROSS MARGIN (%)
2027 est 46.72
2026 est 52.02
2025 55.36
2024 46.19
2023 38.64
2022 35.95
2021 37.53
2020 39.56
2019 45.61
2018 41.16
2017 45.80
2016 49.98
2015 48.69
2014 55.55
2013 53.27
2012 50.52
2011 48.72
2010 48.63
2009 51.98
2008 53.86
Access this data via the Eulerpool API

ReproCell Revenue

ReproCell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.20 B JPY
-908.94 M JPY
-1.02 B JPY
Jan 1, 2021
1.29 B JPY
-1.05 B JPY
-812.57 M JPY
Jan 1, 2022
2.23 B JPY
-647.13 M JPY
-575.09 M JPY
Jan 1, 2023
2.95 B JPY
-356.22 M JPY
-305.31 M JPY
Jan 1, 2024
2.43 B JPY
-409.29 M JPY
-31.42 M JPY
Jan 1, 2025
2.98 B JPY
-130.41 M JPY
103.25 M JPY
Jan 1, 2026 (e)
3.17 B JPY
-638.90 M JPY
74.28 M JPY
Jan 1, 2027 (e)
3.53 B JPY
-711.45 M JPY
157.85 M JPY

ReproCell Margins

ReproCell stock margins

The ReproCell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReproCell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReproCell.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
39.56 %
-75.75 %
-84.72 %
Jan 1, 2021
37.53 %
-81.48 %
-63.17 %
Jan 1, 2022
35.95 %
-28.96 %
-25.74 %
Jan 1, 2023
38.64 %
-12.06 %
-10.34 %
Jan 1, 2024
46.19 %
-16.87 %
-1.29 %
Jan 1, 2025
55.36 %
-4.38 %
3.47 %
Jan 1, 2026 (e)
55.36 %
-20.15 %
2.34 %
Jan 1, 2027 (e)
55.36 %
-20.15 %
4.47 %

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Gross Profit of ReproCell is 1.65 B JPY in 2026.

Gross Profit of ReproCell changed from 1.12 B JPY to 1.65 B JPY, representing a 47.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit ReproCell since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's ReproCell historically and in real time.

Access this data via the Eulerpool API

Income Statement — ReproCell

All Key Metrics — ReproCell